Background-Elevated serum urate levels can lead to gout and are associated with cardiovascular risk factors. We performed a genome-wide association study to search for genetic susceptibility loci for serum urate and gout and investigated the causal nature of the associations of serum urate with gout and selected cardiovascular risk factors and coronary heart disease (CHD). Methods and Results-Meta-analyses of genome-wide association studies (GWAS) were performed in 5 population-based cohorts of the Cohorts for Heart and Aging Research in Genome Epidemiology consortium for serum urate and gout in 28 283 white participants. The effect of the most significant single-nucleotide polymorphism at all genome-wide significant loci on serum urate was added to create a genetic urate score. Findings were replicated in the Women's Genome Health Study (nϭ22 054). Single-nucleotide polymorphisms at 8 genetic loci achieved genome-wide
significance with serum urate levels (Pϭ4ϫ10 Ϫ8 to 2ϫ10 Ϫ242 in SLC22A11, GCKR, R3HDM2-INHBC region, RREB1, PDZK1, SLC2A9, ABCG2, and SLC17A1). Only 2 loci (SLC2A9, ABCG2) showed genome-wide significant association with gout. The genetic urate score was strongly associated with serum urate and gout (odds ratio, 12.4 per 100 mol/L; Pϭ3ϫ10
Ϫ39
) but not with blood pressure, glucose, estimated glomerular filtration rate, chronic kidney disease, or CHD. The lack of association between the genetic score and the latter phenotypes also was observed in the Women's Genome Health Study. Conclusions-The genetic urate score analysis suggested a causal relationship between serum urate and gout but did not provide evidence for one between serum urate and cardiovascular risk factors and CHD. (Circ Cardiovasc Genet. 2010; 3:523-530.)
Key Words: uric acid Ⅲ gout Ⅲ cardiovascular diseases Ⅲ risk factors Ⅲ genome-wide association study Ⅲ Mendelian randomization analysis H yperuricemia is a key risk factor for gout, a common inflammatory arthritis caused by deposition of monosodium urate crystals in the joints and surrounding tissues. 1 Multiple renal transporters contribute to the maintenance of normal serum urate levels, but the identity and regulators of these transporters are incompletely understood.
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Although the role of serum urate in the causal pathway for gout has been well characterized, substantial controversy exists regarding whether elevated serum urate also may be a cause of cardiovascular disease (CVD) risk factors or CVD or whether the association with urate seen in observational studies merely is a consequence of these conditions or an artifact of uncontrolled confounding factors. 2 A recent randomized clinical trial of allopurinol in adolescents with newly diagnosed hypertension suggested that drugs that affect serum urate levels also may reduce blood pressure (BP), further highlighting the potential role of serum urate in the pathogenesis of hypertension. 3 We now expand on work by our consortium 4 and others 5-8 with a genome-wide association study (GWAS) and metaanalysis to identify genetic loci associated with urate and gout in a large sample of 28 283 individuals from 5 populationbased cohorts: the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium. 9 Capitalizing on Mendelian randomization, we then created a new genetic urate score of susceptibility to hyperuricemia and examined its association with gout, BP, glucose, chronic kidney disease (CKD), and coronary heart disease (CHD) to improve causal inference from observational studies. Finally, genetic-score association findings were replicated in a second large cohort, the Women's Genome Health Study (WGHS).
Methods
Five large, population-or community-based cohorts from the CHARGE consortium, including the Atherosclerosis Risk in Communities Study (ARIC), Cardiovascular Health Study (CHS), Framingham Heart Study (FHS), the Rotterdam Study (including RS-I and RS-II), and the Age Gene/Environment Susceptibility (AGES) Reykjavik Study, constituted the discovery cohorts to identify genetic variants associated with urate levels and gout and for the genetic urate score analyses. An additional cohort, the WHGS, was used as a replication cohort to confirm the genetic urate score findings.
Each participant of the CHARGE cohorts provided written informed consent, and study protocols were approved by the institutional review boards of their respective institutions. All members of the WGHS cohort were participants in the Women's Health Study who provided an adequate baseline blood sample for plasma and DNA analysis and who gave consent for blood-based analyses and long-term follow-up; the study has been approved by the Institutional Review Board of the Brigham and Women's Hospital. Additional details pertaining to the study samples, including participant recruitment, phenotype definition, genotyping, imputation, and data quality control are provided in the online-only Data Supplement Methods and online-only Data Supplement Table 1 .
CHD, CVD Risk Factors, and Covariates in the CHARGE Cohorts

CHD and CVD Risk Factors
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using a sphygmomanometer in the seated position following a standard protocol in each study. For subjects treated with antihypertensive medications, 10 mm Hg were added to their SBP values and 5 mm Hg to DBP values to impute the untreated blood pressure. 10 Hypertension was defined as SBP Ն140 mm Hg or DBP Ն90 mm Hg or on antihypertensive treatment. Glucose was obtained after an overnight fast. Diabetes was defined by fasting plasma glucose of at least 126 mg/dL, nonfasting plasma glucose of at least 200 mg/dL, diabetes medication, or self-report. Fasting insulin was measured as described in the online-only Data Supplement. Serum creatinine was determined using a modified kinetic Jaffe reaction in all studies but AGES, which used an enzymatic method. Creatinine values were calibrated statistically, and estimated glomerular filtration rate (eGFR) was calculated using the 4-variable Modification of Diet in Renal Disease Study equation. 11 CKD was defined as eGFR Ͻ60 mL/min per 1.73 m 2 . 12 CHD was defined as incident myocardial infarction (AGES, ARIC, CHS, FHS, RS), fatal CHD (ARIC, CHS, FHS, RS), silent myocardial infarction from ECG (ARIC), sudden cardiac arrest (CHS), percutaneous coronary interventions (AGES), coronary artery bypass graft surgery (AGES, RS), coronary revascularization procedure (ARIC), or percutaneous transluminal coronary angioplasty (RS).
Covariate Measurements
Body mass index (BMI) was calculated as weight in kilograms divided by squared height in meters, alcohol consumption was recorded as drinks per week and converted to grams per week, and antihypertensive treatment was defined as self-reported intake of any antihypertensive medication.
Statistical Analyses in CHARGE Cohorts
GWAS and Meta-analyses
Separate GWAS analyses of Ϸ2.5 million single-nucleotide polymorphisms (SNPs) were first performed within each CHARGE cohort for urate levels, adjusting for age, sex, BMI, alcohol consumption, antihypertensive treatment, study site or cohort, and potential population admixture (online-only Data Supplement Methods and online-only Data Supplement Table 1 ). Fixed-effects meta-analyses then were used to combine the results from all CHARGE cohorts using the software METAL (www.sph.umich.edu/csg/abecasis/metal/index.html). The overall effect size of an SNP from the meta-analyses was defined as the inverse variance-weighted average of the ␤ coefficients for the same allele in each cohort. A threshold of 5ϫ10 Ϫ8 defined genome-wide significance, corresponding to a Bonferroni-adjusted ␣ϭ0.05 for 1 million independent tests, the estimated multiple testing burden for a GWAS of individuals of European ancestry. 13 For gout meta-analyses, SNPs with minor allele frequency Ͻ0.02 were excluded from the analyses to minimize the risk of false-positive results.
Genetic Urate Score Analysis
To model the cumulative effects of the loci identified from the urate metaanalysis, we multiplied for each locus the number of minor alleles of the most significant SNP each person carried (0 to 2) by the ␤ coefficient from the meta-analysis and added the results to calculate a genetic urate score. Specifically, the genetic urate score equals rs1967017(T)ϫ3.3ϩrs780093(T)ϫ5.2Ϫrs13129697(G)ϫ22.2ϩ rs2199936(A)ϫ18.1ϩrs675209(T)ϫ4.4Ϫrs1165196(G)ϫ6.2ϩrs2078267 (C)ϫ6.8Ϫrs1106766(T)ϫ5.2, where each SNP ID followed by the allele in parenthesis denotes the number of copies of that allele carried by an individual, and the number multiplied to is the effect size per copy of the allele in micromole per liter estimated in our meta-analyses. This genetic score calculation is the first of a 2-step least squares instrumental variables analysis to estimate the effect of a genetic score on the intermediary variable (serum urate) in a Mendelian randomization design. 14 The score assigns 0 to individuals who carry all major alleles and has the unit of micromoles per liter. Thus, the genetic urate score is the difference in mean serum urate levels of individuals with a specific combination of genotypes compared to individuals who carry 2 copies of the major alleles at all the susceptibility loci. The genetic urate risk score was then tested for association with CHD and CVD risk factors with limited adjustment for age, sex, and center and more-extensive adjustment for major confounders. 2 Meta-analyzed associations are presented per 100-mol/L (1.68 mg/dL) increase in the genetic urate score because it is similar to the range of the genetic urate score. Because power is a concern for using this approach, we calculated 80% power for each trait for a 1-sided test at ␣ϭ0.05. Details of the power calculation are presented in the online-only Data Supplement Methods.
Replication of Genetic Urate Score Findings in WGHS
An independent cohort of 22 054 from the WGHS was used to validate the genetic urate score findings from the CHARGE cohorts. Details pertaining to the WGHS are included in the online-only Data Supplement Materials and online-only Data Supplement Table 1 .
Results
Characteristics of individual CHARGE cohorts are presented in Table 1 for the 28 283 participants with serum urate levels.
Urate and Gout GWAS Meta-analysis in CHARGE Cohorts
Eight loci (SLC22A11, GCKR, R3HDM2-INHBC region, RREB1, PDZK1, SLC2A9, ABCG2, SLC17A1) showed genome-wide significant association in the meta-analysis for urate (metaanalysis P value range, 3.5ϫ10 Ϫ8 to 1.5ϫ10 Ϫ242 ) ( Table 2) . A genome-wide overview of the P values from the meta-analyses is presented in online-only Data Supplement Figure 1 . Online- (24) 731 (9) 603 (19) 231 (8) 577 (14) 169 (9) CHD 447 (15) 1365 (17) 660 (21) 197 (5) 928 (16) 65 ( §Participants with diabetes were excluded from the analyses.
only Data Supplement Figure 2 presents regional association plots for each of the 8 loci. Details of study-specific GWAS results for the 8 loci are presented in online-only Data Supplement Table 2 and in a forest plot in online-only Data Supplement Figure 3 that demonstrates consistent results across studies. Imputation scores for all loci are shown in online-only Data Supplement Table 3 , indicating generally good imputation quality across cohorts. All the SNPs with meta-analysis PϽ4ϫ10
Ϫ7
are presented in online-only Data Supplement Tables 6 and 7 for serum urate and gout, respectively. Of the loci identified, 6 were also nominally associated with gout (Table 2) . Besides SLC2A9 and ABCG2, a separate GWAS of gout did not identify additional loci reaching genome-wide significance.
Genetic Urate Score Association With Serum Urate and Gout in CHARGE Cohorts
The genetic urate risk score was strongly and linearly associated with serum urate (multivariable adjusted PϽ4.5ϫ10 Ϫ308 ) ( Figure   1 ). The score ranged from Ϫ67 to 76 mol/L and explained an average of 6.0% of serum urate variance compared to an average of 0.8% for the individual SNPs and 3.7% for the strongest SNP (SLC2A9). The gout prevalence varied 10-fold across genetic urate score categories (multivariable adjusted Pϭ5.5ϫ10 Ϫ34 ) (Figure 1 ). Across genes, the odds ratio (OR) for gout was highly correlated with the effect size for serum urate for each additional minor allele (rϭ0.97) (Figure 2 ). Overall, for a 100-mol/L higher genetic urate score, average serum urate was 99.3 mol/L higher, and gout ORs were 12.4 (95% CI, 8.5 to 18.0) times higher ( Table 3) .
Comparison of Serum Urate and Genetic Urate Score Associations With CVD Risk Factors and CHD in CHARGE Cohorts
Serum urate adjusted for age, sex, and center was strongly associated with all of the CVD risk factors examined (PϽ0.001) ( Table 3) . Further covariate adjustment reduced 96  472  985  2483  4369  4996  6366  5107  2295  835  216  48  N  89  400  836  2131  3743  4319  5523  4436  2018  749  197 †MAF was sample size-weighted average of the frequency of the less common allele (minor allele) over all cohorts. ‡␤ coefficients (the increase of uric acid ͓mol/L͔ per copy of the minor allele under an additive model) and their SEs were obtained from inverse variance-weighted meta-analyses.
§Sample size-weighted average of the R 2 coefficient from individual studies (ie, total phenotypic variance explained by the additive effect of SNP genotype). OR for gout per copy increment of the minor allele, obtained from inverse variance-weighted metaanalysis. #SLC17A1 refers to the entire SLC17A4/SLC17A1/SLC17A3/SLC17A2 gene cluster.
the magnitude of the associations, but all associations remained highly significant (PϽ0.001) except for fasting glucose. In contrast, the genetic urate risk score was not associated (PՆ0.05) with SBP, DBP, fasting glucose levels, fasting insulin, eGFR, CKD (nϭ3092 cases) or incident CHD (nϭ3050 cases). Excluding participants on hypertension treatment from the SBP and DBP analyses or participants with diabetes from the glucose analysis made little difference. We evaluated the detectable genetic urate score effect size per 100 mol/L with 80% power (Table 3 , last column) in the context of observed effect sizes of serum urate per 100 mol/L on each phenotype (Table 3 , columns 3 and 5). For gout, fasting glucose, SBP, DBP, and eGFR, our study had good power because the observed serum urate effect sizes are generally higher than the detectable genetic urate effect sizes. For CKD, although the observed effect size is higher than detectable effect size, the detectable effect size (OR, 1.38) is considered high for a genetic association. For CHD, observed serum urate effect size is smaller than the detectable genetic score effect size with 80% power. Therefore, a modest association with CKD and CHD cannot be ruled out due to insufficient power.
Replication in the WGHS
Analyses of the association of the urate risk score with CHD and CVD risk factors in the WGHS demonstrated similar null results (online-only Data Supplement Table 4 ). Per 100-mol/L higher genetic urate score, the age-and sex-adjusted ORs of hypertension incidence was 0.93 (95% CI, 0.78 to 1.11; Pϭ0.43); coefficients for self-reported BP, diabetes, eGFR, and CKD were nonsignificant. The age-and sexadjusted hazard ratio for incidence of CHD was 0.83 (95% CI, 0.53 to 1.30; Pϭ0.42). Similar results were obtained for multivariable-adjusted analyses.
Secondary Analyses Results
We also evaluated the association of individual SNPs with cardiovascular risk factors and CHD to examine possible pleiotropic effects, examined a possible threshold effect of the genetic urate score, and conducted sensitivity analyses for the genetic urate score. Description of these analyses and results is included in the online-only Data Supplement Materials and online-only Data Supplement Table 5 .
Discussion
We have identified genetic variants in 8 genetic loci associated with serum urate, using 5 CHARGE cohorts. Our genetic urate score was strongly associated with a 10-fold variation in gout prevalence. In marked contrast, we did not observe an association between the genetic urate score and BP, fasting glucose, CKD, or CHD. This lack of association also was observed in another independent large cohort, WGHS.
Our GWAS results are similar to another recent GWAS by Kolz et al 8 in Ͼ28 000 European individuals. Six (PDZK1, GCKR, SLC2A9, ABCG2, SLC17A1, SLC22A11) of the 9 loci identified by the authors also were identified in the present study. Among the remaining 3 loci identified in Kolz et al, SLC16A9 and LRRC16 were borderline genome-wide significant (Pϭ1.7ϫ10 Ϫ7 and 1.3ϫ10 Ϫ7 , respectively) in the present study; SLC22A12 reached significance in our study but was not considered as an independent locus because of its proximity with SLC22A11 and the uncertainty that the signals represent independent variants. We also identified the R3HDM2-INHBC region and RREB1.
We confirmed urate transporters ABCG2, SLC2A9, and SLC17A1 identified in our previous GWAS that included a subset of current study cohorts and a subsequent functional study. 4, 15 Among our additional findings, SLC22A11 encodes a known renal urate transporter, OAT4, 16 but it is also in proximity to SCL22A12, which encodes another well-known urate transporter, URAT1. 17 PDZK1 has been shown in experimental settings to interact directly with protein products of SLC22A11 and SLC17A1 and has been proposed as a regulator of urate transport activities. 18 The biological mechanisms underlying the association of SNPs in RREB1, the R3HDM2-INHBC region, and GCKR with serum urate are unknown. RREB1 is a zinc finger transcription factor reported to regulate the androgen receptor and the calcitonin gene. 17, 19 INHBC is a member of the transforming growth factor ␤ superfamily 20 ; the top-associated SNP rs4760254 maps to the intergenic region between the INHBC and R3HDM2 genes. SNPs in GCKR were previously reported in association with higher C-reactive protein, higher triglyceride levels, and lower glucose levels, suggesting pleiotropic mechanisms. 21 Multiple lines of evidence link serum urate levels to hypertension, diabetes, CKD, and CHD. 2, 3 However, epidemiological studies of metabolic traits are limited in determining causation, and serum urate can be elevated secondary to disease or confounders. Because the association between genes and disease generally is not subject to confounding by environmental factors or reverse causality, causal inferences between exposure and disease can be examined more specifically using Mendelian randomization. 14, 22 The percentage of variation explained by the genetic score is moderate. However, power calculation taking into account the variation explained by the genetic score indicated that this study had enough power to detect genetic score effect sizes similar to observed epidemiology effects of urate for all phenotypes but CHD. For the initial analyses only involving CHARGE cohorts, the genetic score has been constructed and tested for association with cardiovascular risk factors in the same individuals. As a result, the genetic score effects may be overestimated and should be interpreted with caution. However, the potential of overestimating effect sizes of the genetic score is contrary to its lack of association with cardiovascular risk factors except gout in CHARGE. A similar lack of association findings has been reported by other studies that examined the association between individual genetic variants for serum urate and cardiovascular risk factors, including BP, hypertension, glucose, lipids, and coronary artery diseases. 6, 23, 24 Taken together, these findings raise questions about whether the observed epidemiological associations between serum urate and CVD risk factors present in our cohorts and previous studies are due to causal associations.
Several limitations of our study pertain to the generalizability of our findings. First, our study focused on CVD risk factors and incident CHD in middle-aged and older individuals and, therefore, could not investigate the association of serum urate levels with BP and newly onset CVD and its risk factors in adolescents and young adults. Second, participants of this study are white; thus, findings may not be generalizable to other ethnicities. Third, gout ascertainment was based on self-report or medication records, which may have resulted in inaccurate disease classification for some individuals and reduced power to detect an association. However, the 2 loci identified associated with gout showed consistent effects across cohorts and were the ones identified by other independent studies, [5] [6] [7] [8] 25 demonstrating the robustness of our results to the gout ascertainment. Fourth, we only tested the association of genetic urate score with CKD defined as eGFR Ͻ60 mL/min per 1.73 m 2 . We were not able to examine more extreme definitions of CKD due to lack of power. Additionally, we were not able to adjust for the effects of antihyperuricemic treatment (eg, allopurinol) in our analyses because information on such treatment was not available in all cohorts. However, ignoring antihyperuricemic treatment is unlikely to have had a substantial impact on our results ‡Effect size detectable with 80% power in the current study with 1-sided PՅ0.05. §For each phenotype, the analysis was restricted to those who had serum urate levels, all multivariable covariates, and gene score available. ␤ coefficients and their SEs were obtained from inverse variance-weighted meta-analyses of individual study results. ¶If participants were treated with antihypertensive medication, 10 mm Hg was added to SBP and 5 mm Hg added to DBP. #Participants taking antihypertensive medication were excluded from the analyses. **Because of the lack of a standard to covert insulin in different studies to the same scale, sample size-weighted meta-analyses were performed instead. Z statistics were reported in place of the ␤ coefficient.
because only a small percentage of the study sample was expected to have been treated. Finally, we modeled a linear association of the genetic score with outcomes. We observed no association when the data were stratified by serum urate at the median. However, we cannot rule out the possibility of a threshold effect where low serum urate levels are protective but higher levels do not show progressively more deleterious cardiovascular effects. Despite these limitations, our study was large and well powered. The findings were consistent across all participating studies and an independent replication sample.
In conclusion, we identified 8 genetic loci associated with serum urate in a GWAS and meta-analyses. Consistent with the association of serum urate and gout, the combined effect of all the genes summarized in a urate genetic risk score is associated with a 10-fold increase of gout risk. Conversely, the urate genetic risk score was not significantly associated with cardiovascular risk factors or CHD, which stands in contrast to the association between serum urate and vascular risk factors observed in epidemiological studies.
